Post by Moderna on X
Moderna@moderna_tx
XModerna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination

7.2K likes0 repliesPosted Aug 19, 2026